Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...

The Department of Health and Human Services (HHS) has canceled funding pledged to Moderna for the development of mRNA-based ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Robert F. Kennedy Jr. continues his anti-vax crusade by cancelling million-dollar bird flu vaccine deal with Moderna.

CAMBRIDGE, MASS. — The US Department of Health and Human Services (HHS) notified pharmaceutical company Moderna Inc. on May ...

The money, awarded last year, was intended to develop a vaccine to protect against potential pandemic influenza viruses, ...

The U.S. Department of Health and Human Services has canceled its $776 million contract with Moderna to develop an mRNA-based ...